Mesalazine Effects in Sporadic Colorectal Adenoma Patients
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Several studies indicate that mesalazine might have a preventive effect on recurrence of
adenomas in patients with and without inflammatory bowel disease. As mesalazine has limited
adverse effects, it is an attractive candidate for chemoprevention. In this study we aim to
investigate the antineoplastic properties of mesalazine in patients with sporadic colorectal
adenomas.